



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**

<http://doi.org/10.5281/zenodo.3353521>

Available online at: <http://www.iajps.com>

*Research Article*

## ROLE OF BRANCHED CHAIN AMINO ACID IN THE ACHIEVEMENT OF HEPATIC ENCEPHALOPATHY EARLY REVERSAL AMONG ADVANCED LIVER DISEASE PATIENTS

<sup>1</sup>Dr. Saba Asghar, <sup>2</sup>Dr Muhammad Hassan Shahbaz, <sup>3</sup>Dr Muhammad Fahad Faiz

<sup>1</sup>DHQ Hospital Skp, <sup>2</sup>Medical officer, Jinnah Diagnostic center Sialkot, Pakistan, <sup>3</sup>Medical officer, Dr. Faiz Lab Sialkot, Pakistan.

**Article Received:** May 2019

**Accepted:** June 2019

**Published:** July 2019

**Abstract:**

**Objectives:** The objective of this research was to compare the occurrence of hepatic encephalopathy early reversal among without BCAA (Branched Chain Amino Acid) liver disease patients.

**Methodology:** This research was carried out at Mayo Hospital, Lahore from August 2017 to July 2018. The research sample included 100 patients who were further divided into groups of fifty each as Group I & II having Grade III or IV Hepatic encephalopathy and Splenomegaly and coarse liver as observed through USG. The patients were selected from both male and female gender having age from 30 to 60 years. Demographic information included address, name, and age which was kept confidential. Data entry and analysis was carried out through SPSS software with documentation of change of hepatic encephalopathy grades.

**Results:** The predominant age group was from 41 to 50 years having a respective representation of 22 patients in Group – I (44%) and 26 patients in Group – II (52%). Mean and SD values for Group I & II were respectively (43.98 ± 3.76) and (44.32 ± 3.02). Group – I had 33 males (66%) and 17 females (34%); whereas, Group – II had 29 males (58%) and 21 females (42%). Hepatic encephalopathy early reversal among advanced liver disease patients with BCAA in Group – I was reported in 32 patients (64%) and in Group – II in 13 patients (26%); whereas, without BCAA in Group – I was in 18 patients (36%) and Group – II in 37 patients (74%) (P-Value = 0.00).

**Conclusion:** The hepatic encephalopathy early reversal occurrence among advanced liver disease patients with BCAA and without BCAA shows that BCAA treated patients achieved hepatic encephalopathy early reversal.

**Keywords:** Early Reversal, Advance Liver Disease, BCAA (Branched Chain Amino Acid), Hepatic Encephalopathy, Grade and Infection.

**Corresponding author:**

**Dr. Saba Asghar,**  
DHQ Hospital Skp

QR code



Please cite this article in press Saba Asghar et al., **Role of Branched Chain Amino Acid in the Achievement of Hepatic Encephalopathy Early Reversal among Advanced Liver Disease Patients.**, Indo Am. J. P. Sci, 2019; 06(07).

**INTRODUCTION:**

HBV & HCV contribute a major disease burden of the globe especially in the setting of under-developed countries; these underdeveloped countries lack better management of healthcare safeties and systems effectively which increases the risk factors; there is a dire need to improve the level of awareness among such countries about the transmission mode and management of HBV & HCV infection [1, 2]. Cirrhosis and CKD cause 35,000 deaths every year in the USA; whereas, Portosystemic encephalopathy is one of the grave complications of CKD [3, 4]. It is a disordered state of the central nervous system which is an outcome of liver failure caused by Porto system shunting and hepatocellular dysfunction [5]. The range of the spectrum varies from night and day and mild cognitive impairment to coma as well [5]. Malnutrition is a crucial complication which an indicator of clinical results such as life quality, prolonged hospitalization, and survival rate among cirrhosis patients [6].

A study shows that BCAA has a vital role in the hepatic encephalopathy early reversal which reduces the burden of extra pumping of resources on health [7]. The research shows that all those who received standard treatment of Group – I the improvement was shown in eleven patients out of forty-four who were in Grade – IV encephalopathy within three days than standard treatment with an addition of BCAA (Group – II) [8]. Hospitalization was also prolonged in Group – I was more than the hospitalization of Group – II that is more than seven days; whereas, only one case remained hospitalized for more than fourteen days.

**METHODOLOGY:**

This research was carried out at Mayo Hospital, Lahore from August 2017 to July 2018. The research sample included 100 patients who were further divided into groups of fifty each as Group I & II having Grade III or IV Hepatic encephalopathy and Splenomegaly and coarse liver as observed through USG. The

patients were selected from both male and female gender having age from 30 to 60 years. We did not include all those patients who had levels of Serum bilirubin (> 5 mg/dl), bleeding of upper GIT, comorbidities such as Diabetes Mellitus, Ischemic heart disease, Hypertension or Chronic kidney disease (CKD). Research commenced after ethical approval of the hospital ethical committee and informed consent of every patient. We also explained the protocols of research with benefits and associated risk of the procedure to all the patients. Demographic information included address, name, and age which was kept confidential. On admission, the hepatic encephalopathy grading was carried out which was repeated after every three days. Non-probability sampling was used to assign groups to patients. Traditional management was extended to Group – I along with a daily dose of 1000 ml BCAA; whereas, Group – II received only conventional hepatic encephalopathy treatment. Data entry and analysis was carried out through SPSS software with documentation of change of hepatic encephalopathy grades.

**RESULTS:**

According to the distribution of age, the predominant age group was from 41 to 50 years having a respective presentation of 22 patients in Group – I (44%) and 26 patients in Group – II (52%). Mean and SD values for Group I & II were respectively ( $43.98 \pm 3.76$ ) and ( $44.32 \pm 3.02$ ). Group – I had 33 males (66%) and 17 females (34%); whereas, Group – II had 29 males (58%) and 21 females (42%). Hepatic encephalopathy early reversal among advanced liver disease patients with BCAA in Group – I was reported in 32 patients (64%) and in Group – II in 13 patients (26%); whereas, without BCAA in Group – I was in 18 patients (36%) and Group – II in 37 patients (74%) (P-Value = 0.00).

Detailed outcomes of Age Distribution (Table – I), Gender Distribution (Table – II) and Group Wise Early Reversal (Table – III) are as under:

**Table – I: Age Distribution**

| Age           | Group – I (50)   |            | Group – II (50)  |            |
|---------------|------------------|------------|------------------|------------|
|               | Number           | Percentage | Number           | Percentage |
| 30 – 40 Years | 13               | 26         | 11               | 22         |
| 41 – 50 Years | 22               | 44         | 26               | 52         |
| 51 – 60 Years | 15               | 30         | 13               | 26         |
| Total         | 50               | 100        | 50               | 100        |
| Mean $\pm$ SD | $43.98 \pm 3.76$ |            | $44.32 \pm 3.02$ |            |




Table – II: Gender Distribution

| Gender | Group – I (50) |            | Group – II (50) |            |
|--------|----------------|------------|-----------------|------------|
|        | Number         | Percentage | Number          | Percentage |
| Male   | 33             | 66         | 29              | 58         |
| Female | 17             | 34         | 21              | 42         |
| Total  | 50             | 100        | 50              | 100        |





Table – III: Group Wise Early Reversal

| Early Reversal | Group – I (50) |            | Group – II (50) |            |
|----------------|----------------|------------|-----------------|------------|
|                | Number         | Percentage | Number          | Percentage |
| Yes            | 32             | 64         | 13              | 26         |
| No             | 18             | 36         | 37              | 74         |
| Total          | 50             | 100        | 50              | 100        |



### DISCUSSION:

It is essential to completely understand the disease pathophysiology in order to get to effective treatment options; sometimes only relying on pathophysiology may lead to erroneous treatments. Effective treatment of hepatic encephalopathy is difficult till the proper prognosis. It is also important to note that few treatments were so much effective even when the mechanism of pathophysiological was no known such as treating scurvy with citrus fruit [9]. Past observations in yeast recommend that BCAAs isoleucine, leucine, and valine have potential survival rates [10]. The intensive debate is also going on the effectiveness of BCAA especially in terms of hepatic encephalopathy [11 – 16].

According to Naylor, the BCAA increases the rate of recovery among acute hepatic encephalopathy patients with an uncertain outcome of mortality [11]. According to Conner, little evidence is available about the effectiveness of BCAA for chronic, acute or minimal hepatic encephalopathy patients [12]. Our research and the outcomes of Naylor are the same about the improved outcomes of BCAA for encephalopathy. Due to reduced quality of the approach, the outcomes research conducted by Eriksson reflects biasness [17 – 20]. Presently, the evidence is limited for the onward recommendation of

BCAA to treat hepatic encephalopathy. However, this research aims to evaluate the effectiveness of BCAA for the treatment of hepatic encephalopathy along with traditional treatment options to reduce hospitalization and mortality rates. Hepatic encephalopathy early reversal among advanced liver disease patients with BCAA in Group – I was reported in 32 patients (64%) and in Group – II in 13 patients (26%); whereas, without BCAA in Group – I was in 18 patients (36%) and Group – II in 37 patients (74%). Afzaal also reported similar outcomes and demonstrated that 56.6% hepatic failure cases of Grade – IV improved to Grade – I who received BCAA than the patients who received only conventional treatment after three days of treatment [21]. We also found that BCAA plays a vital role in the hepatic encephalopathy early reversal among CKD patients. An author also showed an onset of early reversal through BCAA in the mean duration of 56.80 hours [22].

Multiple research evidence are available about the reduced hospitalization due to use of BCAA [23]. A similar observation is also found in this research about the hospitalization. Andrea Fabbri concludes that we may suggest BCAA to only those patients who present an advanced CKD stage [24]. More research work will ultimately benefit the professionals in order to treat hepatic encephalopathy with the addition of BCAA.

**CONCLUSION:**

The hepatic encephalopathy early reversal occurrence among advanced liver disease patients with BCAA and without BCAA shows that BCAA treated patients achieved hepatic encephalopathy early reversal.

**REFERENCES:**

1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does the quality of reports nonrandomized trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet* 1998;352:609-13.
2. Jüni P, Altman D, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. *BMJ* 2001; 323:42-6.
3. Afzal S, Ahmad M. Role of branched-chain amino acids in a reversal of hepatic encephalopathy. *Ann King Edward Med Uni*2010;16(2):108-111.
4. Tangkijvanich P, Mahachai V, Wittayalertpanya S, Ariya Wongsophon V, Sachapan I. Short term effects of branched-chain amino acids on liver function tests in cirrhotic patients. *Southeast Asian J Trop Med Public Health* 2006;31(1):152-7.
5. Khan IM, Hameed K, Ahmad S, Khan A, Akbar F. Effects of amino Laban unconsciousness level of liver disease. *Postgrad Med Inst* 2003;17(2):163-7.
6. Andrea Fabbri, Nicola Magrini, Bianchi G, Marchesini G. Overview of Randomized Clinical Trials of Oral Branched-Chain Amino Acid Treatment in Chronic Hepatic Encephalopathy. *Journal of Parenteral and*
7. *Enteral Nutrition* 2006;20(2):159-64.
8. Bemeur C, Desjardins P, Butterworth RF. Role of Nutrition in the Management of Hepatic Encephalopathy in End-Stage Liver Failure. *J Nutr Metab* 2010; 2010:489823.
9. Afzal S, Ahmad M. Role of Branched Chain Amino Acids in Reversal of Hepatic Encephalopathy. *Annals* 2010; 16 (2): 108-111.
10. Soomro AA, Devrajani BR, Ghori RA. Role of Branched Chain Amino Acids in the Management of Hepatic Encephalopathy. *World J Med. Sci* 2008; 3 (2): 60-64.
11. Doust J, Del Mar C. Why do doctors use treatments that do not work? *BMJ* 2004; 328:474-5.
12. Alvers AL, Fishwick LK, Wood MS, Hu D, Chung HS, Dunn WA, and Aris JP. Autophagy and amino acid homeostasis are required for chronological longevity in *Saccharomyces cerevisiae*. *Aging Cell*. 2009; 8:353-69.
13. Naylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched chain amino acids in hepatic encephalopathy. A meta-analysis. *Gastroenterology*1989; 97:1033-42.
14. Eriksson LS, Conn H.O. Branched-chain amino acids in the management of hepatic encephalopathy: an analysis of variants. *Hepatology* 1989;10:228-46.
15. Ferenci P. Branched-chain amino acids in hepatic encephalopathy. *Gastroenterology*1990; 98:1395-6.
16. Eriksson LS, Conn HO. Branched-chain amino acids in hepatic encephalopathy. *Gastroenterology* 1990; 99:604-7.
17. Gluud C. Branched-chain amino acids for hepatic encephalopathy? *Hepatology*1991; 13:812-3.
18. Naylor CD. Branched-chain amino acids in hepatic encephalopathy. Continuing controversy. *Int J Technol Assess Health Care*1991; 7:648-50.
19. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995; 273:408-12.
20. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. *Ann Intern Med* 2001; 135:982-9.
21. Lavanchy D. The global burden of hepatitis C. *Liver Int* 2009, 29(s1):74–81.
22. Rantala M, Van de Laar M JW. Surveillance and epidemiology of hepatitis B and C in Europe – a review. *Euro surveillance* 2008,13(4–6):1–8.
23. Wolf DC. Cirrhosis. *Medscape* 2011; Last accessed: 12th March 2012. Available at: <http://emedicine.medscape.com/article/185856-overview>.
24. Longo DL, Fauci AS, Kasper DL. Cirrhosis and Its Complications. In: editors. *Harrison's principles of Internal Medicine*. 18th Ed. United States of America: Mc Graw Hill Companies; Vol 2. 2012: p2601.
25. McPhee SJ, Papadakis MA. Liver, Biliary Tract, & Pancreatic Disorders. In: editors. *Current Medical Diagnosis & Treatment*. 49thEd. United States of America: Mc Graw Hill Companies; 2010: p622.